Welcome to our dedicated page for Theralase Technologies news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies stock.
Theralase Technologies Inc. (TLTFF) is a clinical stage pharmaceutical company dedicated to developing light and/or radiation activated small molecules for effectively destroying cancers, bacteria, and viruses. Their lead compound, RuvidarTM, has shown promise in inactivating various viruses and increasing efficacy in cancer cell destruction. Recent research has demonstrated RuvidarTM's ability to reverse the charge of BCG, creating a compound, RuBCG, with enhanced cancer cell kill rates. Additionally, Rutherrin® has proven effective in increasing chemotherapy efficacy and reducing multidrug resistance in cancer cells. Theralase is committed to advancing innovative therapies to combat challenging diseases and improve patient outcomes.
Rhea-AI Summary
Theralase Technologies Inc. announces hosting of Advisory Board meetings to present Study II interim clinical data for Bacillus Calmette Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. The Company focuses on developing light activated Photo Dynamic Compounds for cancer treatment. The meetings will update Principal Investigators at the Canadian Urological Association and American Urology Association forums. Chief Scientific Officer highlights the potential of Ruvidar-based photodynamic therapy for patients with treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Theralase Technologies Inc. donates Theralase TLC-2400 Cool Laser Therapy systems to aid in Parkinson's Disease research at the University of Windsor. The collaboration aims to study the potential of CLT in treating Parkinson's, showcasing positive outcomes in preliminary studies and animal experiments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Theralase Technologies Inc. announces the appointment of Dr. Michael Jewett as an independent consultant to assist in the completion of patient enrollment in the Phase II clinical study for the treatment of non-muscle invasive bladder cancer. The company aims to enroll 100 patients by the end of 2024 to potentially secure regulatory approval by 2027. Dr. Jewett's impressive background in surgical oncology and his advocacy for patient-centered care make him a valuable addition to the team. Theralase's photodynamic therapy technology has shown promising efficacy and safety profiles in treating BCG-Unresponsive NMIBC CIS, with high response rates and minimal side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Theralase Technologies Inc. successfully closed a non-brokered private placement offering of units, issuing 6,666,670 units at a price of $CAN 0.18 per unit for gross proceeds of approximately $CAN 1,200,000. The company plans to use the proceeds for furthering the Phase II Non-Muscle Invasive Bladder Cancer clinical study, preclinical research and development of Rutherrin, working capital, and general corporate purposes. The offering is subject to a four-month hold period and final acceptance from the TSX Venture Exchange.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
-
Rhea-AI Summary
Theralase Technologies Inc. provides an update on its Phase II Non-Muscle Invasive Bladder Cancer clinical study, showcasing interim clinical data that exceeds International Bladder Cancer Group guidelines. The study demonstrates a complete response of 54% at 6 months, 38% at 12 months, and 37% at 15 months. Additionally, 62% of patients who received the optimized treatment achieved a complete response at 90 days, and 68% achieved a total response. The company has submitted a pre-Breakthrough Designation submission to the FDA and plans to complete enrollment and delivery of the primary study treatment for all patients in 2024, aiming for potential Health Canada and FDA approval by 2026 / 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Theralase Technologies Inc. (TLT) released its 3Q2023 unaudited condensed interim consolidated Financial Statements, reporting a 13% decrease in total revenue. The company experienced a 32% decrease in net research and development expenses for the Drug Division, but a 36% increase in administrative expenses. Theralase also closed a non-brokered private placement, raising over $1.1 million in gross proceeds. The company is working on a Break Through Designation submission to the FDA and provided preliminary clinical data for Study II, demonstrating promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
Rhea-AI Summary
Theralase Technologies Inc. (TLT) successfully closed a non-brokered private placement offering, raising approximately $CAN 1,170,000 to further the Phase II Non-Muscle Invasive Bladder Cancer clinical study and for working capital needs. The Corporation issued 5,318,183 Units at $0.22 per Unit, each consisting of one Common Share and one Warrant. Insider subscriptions accounted for $101,482 of the gross proceeds, constituting a related party transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
-
Rhea-AI Summary
Theralase® Technologies Inc. (TLT) has initiated a non-brokered private placement of units to raise up to $CAN 1.5 M. Each unit is priced at $CAN 0.22 and includes one common share and one common share purchase warrant. The company plans to use the proceeds for the Phase II Non-Muscle Invasive Bladder Cancer clinical study and working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
-
Rhea-AI Summary
Theralase Technologies Inc. announces an agreement with Research Capital Corporation for a brokered offering of units at a price of C$0.22 per unit. The offering will raise a minimum of C$3,500,000 and a maximum of C$5,300,000. The company plans to use the proceeds for a clinical study and working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.05%
Tags
Rhea-AI Summary
Theralase Technologies has been granted a Clinical Trial Application Amendment by Health Canada for the optimization of the Phase II Non-Muscle Invasive Bladder Cancer clinical study. The optimization includes post-study monitoring of response, optional maintenance treatments, and central pathology laboratory review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
FAQ
What is the current stock price of Theralase Technologies (TLTFF)?
The current stock price of Theralase Technologies (TLTFF) is $0.17 as of March 3, 2025.
What is the market cap of Theralase Technologies (TLTFF)?
The market cap of Theralase Technologies (TLTFF) is approximately 47.6M.
What is Theralase Technologies Inc. focused on?
Theralase is dedicated to developing light and/or radiation activated small molecules for effectively destroying various cancers, bacteria, and viruses.
What is RuvidarTM and its significance?
RuvidarTM is Theralase's lead compound, proven effective in inactivating viruses and increasing cancer cell destruction efficacy.
How does RuvidarTM impact BCG in cancer treatment?
RuvidarTM reverses the charge of BCG, creating RuBCG, which enhances cancer cell kill rates in bladder cancer therapy.
What is the role of Rutherrin® in chemotherapy?
Rutherrin® effectively increases chemotherapy efficacy and reduces multidrug resistance in cancer cells, offering potential in improving cancer treatment.
What is Theralase's commitment to innovation in healthcare?
Theralase is dedicated to advancing innovative therapies to combat challenging diseases, enhance treatment outcomes, and improve patient quality of life.
Theralase Technologies Inc